~~<i id='7799206E8A'><strike id='7799206E8A'><tt id='7799206E8A'><pre id='7799206E8A'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

focus

entertainment

author：hotspot 2025-09-27 22:05:52 - browse：65

Sarepta Therapeutics said Monday afternoon that its gene therapy for Duchenne muscular dystrophy failed to improve muscle function compared to a placebo in a large clinical trial — likely a major disappointment for patients and doctors who have been desperately awaiting the treatment for years.

The company said all patients in the study improved and that secondary measurements indicated the drug was having an effect. Nevertheless, the results are likely to raise questions about whether the Food and Drug Administration will expand access to the medicine.

Trading in Sarepta shares was halted at $107 with the release of the study results.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Psychedelics group wrestles with new pharma identity
Next article： With trial win, GSK could get blood cancer drug back on market

entertainment

focus

hotspot

leisure time

Wikipedia

focus

MoreolderadultshavebeenhospitalizedforCovid-19overthepastseveralweeks,accordingtodatareviewedbyhealt

WSS

Readout LOUD podcast: ASCO preview, a Duchenne trial failure

ASCO: AstraZeneca's Tagrisso greatly slowed some lung cancers

AstraZeneca chief proposes a novel edit to the drug pricing bill

'Make People Better': The CRISPR babies story you probably don't know

With trial win, GSK could get blood cancer drug back on market

Readout LOUD podcast: ASCO preview, a Duchenne trial failure

focus

entertainment

entertainment

Psychedelics group wrestles with new pharma identity

ASCO: AstraZeneca's Tagrisso greatly slowed some lung cancers

After affirmative action ruling, medical educators look to 'holistic review'

Let's speed up science by embracing open access publishing

The high cost of giving birth even with insurance

ASCO: AstraZeneca's Tagrisso greatly slowed some lung cancers

Wildfire smoke exposes gaps in outdoor worker protections

How to increase colonoscopy rates? Looks like an AI can help

After affirmative action ruling, medical educators look to 'holistic review'

At ASCO, AstraZeneca reports strong data for breast cancer drug

focus

Stem cell treatment guidelines are released by FDA

FDA's Pazdur wants cancer trials to range beyond China alone

For one rare type of lung cancer, Pfizer pill reduces progression by 81%

The 10 drugs up first for Medicare price negotiation

Crinetics acromegaly drug succeeds in late

What American doctors can learn from their Israeli counterparts

hotspot

leisure time

Wikipedia

focus